OX03050 is a metabolically stable, potent and selective squalene synthase inhibitor that upregulates the Low-Density Lipoprotein Receptor (LDLR) in mouse and in human liver cell lines. OX03050 used in conjunction with statin acts synergistically to increase LDLR expression
The Journal of pharmacology and experimental therapeutics, 361(3), 417-428 (2017-04-01)
Hypercholesterolemia remains one of the leading risk factors for the development of cardiovascular disease. Many large double-blind studies have demonstrated that lowering low-density lipoprotein (LDL) cholesterol using a statin can reduce the risk of having a cardiovascular event by approximately
Questions
Reviews
★★★★★ No rating value
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.